Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29608349 | 0.84 | POLB (0.48) | ACHEPOLBALDH1A1TP53 | |
| SCHEMBL4525381 | 0.77 | METAP1 (0.49) | ACHESIGMAR1HTR1AALDH1A1 | |
| SCHEMBL27646285 | 0.75 | SIGMAR1 (0.68) | ACHECYP19A1SIGMAR1DRD2HTR2A | |
| SCHEMBL9136863 | 0.75 | KMT2A (0.43) | ACHESIGMAR1DRD2HTR2AHTR2C | |
| SCHEMBL27014158 | 0.72 | DRD2 (0.57) | ACHECYP19A1SIGMAR1DRD2HTR2A | |
| SCHEMBL9593095 | 0.70 | KDM4E (0.55) | CYP19A1SIGMAR1DRD2HTR2AHTR2C | |
| SCHEMBL9593422 | 0.70 | CYP2D6 (0.52) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL7623809 | 0.70 | CHRNA7 (0.46) | ACHE | |
| SCHEMBL20061129 | 0.70 | ACHE (0.40) | ACHEKDM4EALDH1A1 | |
| SCHEMBL12429578 | 0.70 | CYP19A1 (0.42) | ACHECYP19A1SIGMAR1DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ, INC. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | PINK1, NME4, AK2 | ACHE 1644/4885CYP19A1 4264/4885SIGMAR1 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.